Alderley Park, 22 November 2022 – Blueberry Therapeutics are pleased to announce that their novel cream formulation for the treatment of atopic dermatitis (BB1511) has been nominated for clinical development.
This nomination decision was unanimous following review of pharmaceutical development and pre-clinical data, which demonstrated the required drug attributes to progress towards regulatory advice and then clinical trials. The nomination of BB1511 followed on from the development of BB0107, which although did not quite meet our high standards for nomination, provided valuable insight to allow us to adapt the formulation development for BB1511.
BB1511 is a light cream formulation designed to support skin barrier function whilst reducing the inflammation associated with atopic dermatitis, which we hope will help many patients in managing their disease more effectively.
BB1511 adds to our expanding drug portfolio in the clinical phase (alongside BB2603 for onychomycosis and BB1202 for tinea pedis).
For more information about Blueberry Therapeutics please contact:
Dr Emma Leigh, Director of Communications
info@blueberrytherapeutics.com
About Blueberry Therapeutics
Blueberry Therapeutics is a pharmaceutical company focused on the discovery, development and commercialisation of high value medicines for the treatment of common dermatological conditions that will positively impact on treatment outcomes and improve patient quality of life.
Blueberry applies innovative technologies to improve the delivery of existing drugs through the skin and nail. This enables better efficacy, safety and patient compliance while reducing drug dosage and cost of goods. The Company has a de-risked portfolio of best-in-class [advanced stage] clinical and preclinical assets addressing high value and poorly served indications in dermatology, including onychomycosis (fungal nail infection), tinea pedis (athletes’ foot) and atopic dermatitis (eczema).